MDT-AP-3329
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 5.9
- sex
- M
- new_clusters
- C4
- umap1_2d
- 4.474728938
- umap2_2d
- 2.241587887
- umap1_3d
- 1.852888183
- umap2_3d
- -2.831422951
- umap3_3d
- -2.27151113
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.430
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.370
- TGF_BETA_SIGNALING+0.250
- PROTEIN_SECRETION+0.230
- SPERMATOGENESIS+0.170
- UV_RESPONSE_DN+0.100
- ANDROGEN_RESPONSE+0.090
- DNA_REPAIR+0.080
- PI3K_AKT_MTOR_SIGNALING+0.070
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- MYOGENESIS-0.350
- COAGULATION-0.340
- UV_RESPONSE_UP-0.340
- HYPOXIA-0.320
- ESTROGEN_RESPONSE_EARLY-0.290
- APICAL_SURFACE-0.280
- ESTROGEN_RESPONSE_LATE-0.270
- KRAS_SIGNALING_DN-0.260
- GLYCOLYSIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3043 | Med | Medulloblastoma | 0.833 |
| 2 | TCGA-BH-A18P-01A-11R-A12D-07 | — | A | 0.786 |
| 3 | MDT-AP-3199 | Med | Medulloblastoma | 0.781 |
| 4 | SRR3147748 | — | — | 0.778 |
| 5 | MDT-AP-3245 | Med | Medulloblastoma | 0.776 |
| 6 | MDT-AP-3311 | Med | Medulloblastoma | 0.763 |
| 7 | ERR2598089 | fetal | fetal | 0.763 |
| 8 | MDT-AP-3288 | Med | Medulloblastoma | 0.758 |
| 9 | SRR650203 | — | — | 0.758 |
| 10 | SJEPD030972_D1.RNA-Seq | EPN | Supratentorial EPN | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |